D.E. Shaw & Co
IMDX

D.E. Shaw & Co’s Insight Molecular Diagnostics IMDX Stock Holding History

D.E. Shaw & Co’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,915
Closed -$28K – 5036
2022
Q3 		$28K Sell
1,915
-2,190
-53% -$37.9K ﹤0.01% 4766
2022
Q2 		$74K Sell
4,105
-8,188
-67% -$186K ﹤0.01% 4781
2022
Q1 		$366K Sell
12,293
-4,062
-25% -$130K ﹤0.01% 4549
2021
Q4 		$710K Buy
16,355
+6,124
+60% +$352K ﹤0.01% 4179
2021
Q3 		$729K Buy
10,231
+8,388
+455% +$771K ﹤0.01% 3834
2021
Q2 		$212K Buy
+1,843
New +$180K ﹤0.01% 4424

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's IMDX Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 1,915 shares — an estimated $28K sold.

D.E. Shaw & Co first reported a position in IMDX in Q2 2021 and held it in 6 quarters. The position peaked at $729K in Q3 2021. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,915 Insight Molecular Diagnostics shares in Q4 2022, an estimated $28K.
  • D.E. Shaw & Co first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 6 quarters.
  • D.E. Shaw & Co's Insight Molecular Diagnostics position peaked at $729K in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.